Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotmayer, Lili, László, Tamás, Mikala, Gábor, Kiss, Richárd, Lévay, Luca, Hegyi, Lajos László, Gróf, Stefánia, Nagy, Tibor, Barna, Gábor, Farkas, Péter, Weisinger, Júlia, Nagy, Zsolt, Balogh, Alexandra, Masszi, Tamás, Demeter, Judit, Sulák, Adrienn, Kohl, Zoltán, Alizadeh, Hussain, Egyed, Miklós, Pettendi, Piroska, Gergely, Lajos, Plander, Márk, Pauker, Zsolt, Masszi, András, Matolcsy, András, Szász, Róbert, Bödör, Csaba, Alpár, Donát
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058128/
https://www.ncbi.nlm.nih.gov/pubmed/36982875
http://dx.doi.org/10.3390/ijms24065802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058128/
https://www.ncbi.nlm.nih.gov/pubmed/36982875
http://dx.doi.org/10.3390/ijms24065802

Ejemplares similares